- Home
- GLPG vs AI Comparison
GLPG vs AI Comparison
Compare GLPG & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- AI
- Stock Information
- Founded
- GLPG 1999
- AI 2009
- Country
- GLPG Belgium
- AI United States
- Employees
- GLPG N/A
- AI N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- AI Computer Software: Prepackaged Software
- Sector
- GLPG Health Care
- AI Technology
- Exchange
- GLPG Nasdaq
- AI Nasdaq
- Market Cap
- GLPG 2.1B
- AI 2.4B
- IPO Year
- GLPG 2005
- AI 2020
- Fundamental
- Price
- GLPG $30.42
- AI $13.55
- Analyst Decision
- GLPG Hold
- AI Hold
- Analyst Count
- GLPG 4
- AI 15
- Target Price
- GLPG $31.33
- AI $24.62
- AVG Volume (30 Days)
- GLPG 169.3K
- AI 6.1M
- Earning Date
- GLPG 11-05-2025
- AI 12-03-2025
- Dividend Yield
- GLPG N/A
- AI N/A
- EPS Growth
- GLPG N/A
- AI N/A
- EPS
- GLPG N/A
- AI N/A
- Revenue
- GLPG $336,643,201.00
- AI $372,104,000.00
- Revenue This Year
- GLPG $1.77
- AI N/A
- Revenue Next Year
- GLPG $0.44
- AI $11.61
- P/E Ratio
- GLPG N/A
- AI N/A
- Revenue Growth
- GLPG 10.31
- AI 14.34
- 52 Week Low
- GLPG $22.36
- AI $13.20
- 52 Week High
- GLPG $37.78
- AI $45.08
- Technical
- Relative Strength Index (RSI)
- GLPG 41.14
- AI 29.84
- Support Level
- GLPG $30.17
- AI $13.20
- Resistance Level
- GLPG $33.12
- AI $14.15
- Average True Range (ATR)
- GLPG 0.75
- AI 0.91
- MACD
- GLPG -0.04
- AI -0.25
- Stochastic Oscillator
- GLPG 22.55
- AI 7.51
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About AI C3.ai Inc.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.